Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial
Year: 2025
Type: article
Language: en
Topic: Thyroid Cancer Diagnosis and Treatment
Authors and affiliations:
raw_author_name: Xin Zhang
raw_affiliation_strings: Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China
raw_author_name: Di Sun
raw_affiliation_strings: Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Department of Nuclear Medicine, Peking University People's Hospital, Beijing, China
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China
raw_author_name: Yingqiang Zhang
raw_affiliation_strings: Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China
raw_author_name: Zhuanzhuan Mu
raw_affiliation_strings: Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China
Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
raw_author_name: Cong Shi
raw_affiliation_strings: Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China
raw_author_name: Yuqing Sun
raw_affiliation_strings: Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Department of Nuclear Medicine, Beijing Tsinghua Changgeng Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China
raw_author_name: Xinqi Cheng
raw_affiliation_strings: Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and, Chinese Academy of Medical Sciences , Beijing, China
Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and, Chinese Academy of Medical Sciences
, Beijing, China
raw_author_name: Chao Meng
raw_affiliation_strings: Department of Oncology, Peking University International Hospital, Beijing, China
raw_author_name: Xing Wei
raw_affiliation_strings: Department of Oncology, Peking University International Hospital, Beijing, China
raw_author_name: Jun Liang
raw_affiliation_strings: Department of Oncology, Peking University International Hospital, Beijing, China
raw_author_name: Yansong Lin
raw_affiliation_strings: Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China. linyansong1968@163.com
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China. linyansong1968@163.com
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China